Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 3Diagnosis: Hematopoietic Stem Cell TransplantNCT ID: NCT00785525
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 06-700
The purpose of the study is to: - Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors - Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis - Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients - Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors
Conducting Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital
Overall PI: Thomas Spitzer, MD,
Massachusetts General Hospital
Site-responsible Investigators: Joseph Antin, MD,
Dana-Farber Cancer Institute
Contacts: Dana-Farber Cancer Institute:
Margaret Coles, 617-632-4890,
firstname.lastname@example.orgMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100